Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Notice of Results and Investor Presentation
LONDON, 26 May 2023: Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing and sale of breakthrough cannabis-based medicines, will announce its results for the year ended 31 December 2022 on Monday 5 June 2023.
Analyst Briefing: 10.00am, Monday 5 June 2023
Management will host a virtual analyst presentation followed by a Q&A session at 10.00am BST on Monday 5 June 2023. Analysts wishing to join should register their interest by contacting celadon@powerscourt-group.com.
Investor Presentation: 3.30pm, Monday 5 June 2023
Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 3.30pm BST on Monday 5 June 2023.
The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am on Monday 5 June 2023 or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor
Investors who already follow Celadon on the Investor Meet Company platform will automatically receive an invitation to the event.
Enquiries:
| Celadon Pharmaceuticals Plc |
|
| James Short Arthur Wakeley | Via Powerscourt |
|
|
|
| Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
| Bobbie Hilliam / Andrew Potts / Patrick Dolaghan | +44 (0)20 7523 8000 |
| | |
| Powerscourt Group | |
| Sarah MacLeod / Nick Johnson / Sam Austrums / Ibrahim Khalil | +44 (0)20 7250 1446 celadon@powerscourt-group.com |
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and manufacturing and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its GMP pharmaceutical cannabis product. The Company's subsidiary, LVL, owns a MHRA conditionally-approved clinical trial using cannabis based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics which is developing a licenced cannabinoid medicine to treat children with Autism Spectrum Disorder.
For further information please visit our website www.celadonpharma.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
